New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 6, 2014
10:01 EDTALGT, APC, ED, YUM, TIF, SBLK, NS, NTI, NM, MTRN, KIRK, IPHI, HA, HEES, COG, BOBE, BIIB, AXLL, TEVAOn The Fly: Analyst Upgrade Summary
Allegiant Travel (ALGT) upgraded to Outperform from Market Perform at Raymond James... Axiall (AXLL) upgraded to Buy from Neutral at Goldman... Biogen (BIIB) upgraded to Outperform from Market Perform at BMO Capital... Bob Evans (BOBE) upgraded to Buy from Hold at Miller Tabak... Cabot Oil & Gas (COG) upgraded to Buy from Neutral at UBS... H&E Equipment (HEES) upgraded to Buy from Neutral at UBS... Hawaiian Holdings (HA) upgraded to Buy from Hold at Deutsche Bank... Inphi (IPHI) upgraded to Buy from Hold at Jefferies... Kirkland's (KIRK) upgraded to Buy from Hold at KeyBanc... Materion (MTRN) upgraded to Buy from Hold at KeyBanc... Navios Maritime (NM) upgraded to Buy from Hold at Stifel... Northern Tier (NTI) upgraded to Overweight from Equal Weight at Barclays... NuStar Energy (NS) upgraded to Overweight from Neutral at JPMorgan... Star Bulk Carriers (SBLK) upgraded to Buy from Hold at Stifel... Tiffany (TIF) upgraded to Buy from Neutral at Citigroup... Yum! Brands (YUM) upgraded to Outperform from Neutral at RW Baird... Consolidated Edison (ED) upgraded to Buy from Hold at Argus... Anadarko (APC) upgraded to Buy from Hold at Argus... Teva (TEVA) upgraded to Outperform from Market Perform at Leerink.
News For ALGT;AXLL;BIIB;BOBE;COG;HEES;HA;IPHI;KIRK;MTRN;NM;NTI;NS;SBLK;TIF;YUM;ED;APC;TEVA From The Last 14 Days
Check below for free stories on ALGT;AXLL;BIIB;BOBE;COG;HEES;HA;IPHI;KIRK;MTRN;NM;NTI;NS;SBLK;TIF;YUM;ED;APC;TEVA the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
September 12, 2014
09:01 EDTTEVATeva to present Copaxone gene expression analysis
Subscribe for More Information
08:06 EDTTEVATeva presents new clinical safety data in RRMS patients treated with Laquinimod
Teva (TEVA) and Active Biotech (ACTI) announced new follow-up data evaluating the clinical safety of laquinimod in patients with relapsing-remitting multiple sclerosis, or RRMS, who were treated with laquinimod in Phase II, Phase III and open-label extension studies for two or more years. The pooled safety analysis of the Phase II LAQ/5063 and the Phase III ALLEGRO and BRAVO extension studies supports findings observed in the core studies where currently identified risks were observed within the first months of laquinimod treatment. In the pooled safety analysis, rates of adverse events, or AEs, and serious AEs were lower in the open-label extensions than in the core studies and less than three percent of patients discontinued treatment due to AEs during these extensions. Additionally, shifts to potentially significant laboratory values were considerably lower in patients exposed to at least two years of laquinimod.
08:03 EDTTEVATeva, Active Biotech present laquinimod follow-up data
Subscribe for More Information
07:32 EDTBIIBBiogen, AbbVie announce ZINBRYTA DECIDE Phase 3 study results
Biogen (BIIB) and AbbVie (ABBV) announced the full results from the Phase 3 DECIDE clinical trial, which show ZINBRYTA, dosed subcutaneously once a month, demonstrated a statistically significant improvement in reducing disease activity in people with relapsing-remitting multiple sclerosis compared to AVONEX. These results are being presented at the Sixth Triennial Joint Meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis and the European Committee for Treatment and Research in Multiple Sclerosis. Patients on ZINBRYTA demonstrated a statistically significant 45% reduction in annualized relapse rate compared to patients treated with AVONEX. Based on the efficacy and safety data from the ZINBRYTA clinical development program, Biogen Idec and AbbVie plan to file marketing applications for ZINBRYTA with regulatory authorities during 1H15.
September 11, 2014
16:02 EDTALGTAllegiant Travel announces repurchase of 200K shares from chairman, CEO
Subscribe for More Information
09:39 EDTTIFTiffany management to meet with Topeka
Meeting to be held in Boston on September 16 hosted by Topeka.
09:31 EDTTEVATeva announces new data from Phase IIIb GLACIER study
Subscribe for More Information
07:31 EDTBIIBBiogen announces 5-year results from TECFIDERA ENDORSE Phase 3 study
Subscribe for More Information
07:31 EDTBIIBBiogen announces new data from Plegridy Phase 3 ADVANCE trial
Biogen Idec announced new data from the second year of its Phase 3 ADVANCE clinical trial that show the positive treatment effects of PLEGRIDY were maintained in people with relapsing forms of multiple sclerosis beyond the first year of the study. These results were presented at the sixth Triennial Joint Meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis and the European Committee for Treatment and Research in Multiple Sclerosis in Boston. Post-hoc analyses from the two-year, Phase 3 ADVANCE clinical trial confirm that PLEGRIDY’s positive effects on reducing disease activity and disability progression were maintained in year two of the study. A significantly higher proportion of patients taking PLEGRIDY during both years of the study experienced no evidence of disease activity – defined as the absence of clinical and MRI disease activity over two years of treatment – compared to those who switched to PLEGRIDY from placebo. Also, those treated with PLEGRIDY for both years of the study had significant reductions in the risk of 24-week confirmed disability progression compared to patients treated with placebo during the first year. In addition, new data from the second year of ADVANCE show that patients who took PLEGRIDY throughout the study experienced statistically significant improvements in clinical and MRI outcomes – including annualized relapse rate, risk of relapse, risk of 24-week confirmed disability progression, and number of brain lesions – when compared to those who switched to PLEGRIDY after taking placebo for the first year. This new data also showed that the safety profile of PLEGRIDY was consistent between years one and two of the study.
03:27 EDTTEVATeva Canada announces launch of generic version of Cipralex
Subscribe for More Information
September 10, 2014
16:15 EDTYUMYum! Brands increases quarterly dividend 11% to 41c from 37c
Subscribe for More Information
14:25 EDTTEVATeva Canada announces launch of generic version of Cipralex
Subscribe for More Information
10:00 EDTTIFOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
08:51 EDTTIFTiffany downgraded at Credit Suisse
Subscribe for More Information
06:19 EDTTIFTiffany downgraded to Neutral from Outperform at Credit Suisse
Subscribe for More Information
September 9, 2014
16:02 EDTHAHawaiian Airlines reports August RPMs up 4%
Subscribe for More Information
September 8, 2014
12:40 EDTTEVAFTC sues AbbVie over blocking of AndroGel generics
The Federal Trade Commission has filed a complaint in federal district court charging several pharmaceutical companies with "illegally blocking American consumers’ access to lower-cost versions of the blockbuster drug AndroGel." The FTC's complaint alleges that AbbVie (ABBV) and its partner Besins Healthcare filed baseless patent infringement lawsuits against potential generic competitors to delay the introduction of lower-priced versions of the testosterone replacement drug AndroGel. While the lawsuits were pending, AbbVie then entered into an anticompetitive pay-for-delay settlement agreement with Teva Pharmaceuticals (TEVA) to further delay generic drug competition, the FTC claims. Reference Link
09:27 EDTBIIB, TEVALeerink biotech analyst holds a luncheon meeting with a conference call
Biotech Analyst Schwartz provides an update on key trends and controversies for marketed MS therapies and discusses new data presented at ACTRIMS-ECTRIMS at a Luncheon Meeting with an Analyst/Industry conference call to be held in Boston on September 11 at 12:15 pm.
08:02 EDTTEVATeva completes Reslizumab Phase III program
Subscribe for More Information
07:15 EDTBIIBIBC Life Sciences to hold a conference
10th Annual Cell Line Development & Engineering Conference to be held in Berkeley, California on September 8-10.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use